Paper Details

  1. Home
  2. Paper Details

The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy.

Author: , BurchardiN, HankerL C, HarterP, LoiblS, MeierW, PfistererJ, Pujade-LauraineE, Ray-CoquardI, SehouliJ, du BoisA

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.

Overview

A maximum of three lines of chemotherapy is beneficial for patients with recurrent ovarian cancer. Optimal primary tumor debulking and platinum sensitivity remain significant prognostic factors even after multiple relapses.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Despite recent progress in the treatment of ovarian cancer, the majority of patients eventually relapse. There is little information on the effectiveness of chemotherapy in higher treatment lines. PATIENTS AND METHODS: Characterization of the second to sixth line therapy and its effects...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/annonc/mds203

データ提供：米国国立医学図書館（NLM）

Navigating the Desert of Relapsed Ovarian Cancer

Ovarian cancer, a challenging disease, often requires multiple lines of treatment. This study, published in the journal Gynecologic Oncology, examines the impact of second to sixth line therapy on the survival of patients with relapsed ovarian cancer.

The authors, like researchers navigating a complex and ever-changing desert landscape, analyzed data from three large clinical trials involving 1,620 patients. They found that subsequent lines of therapy, particularly those involving platinum-based regimens, were associated with improved progression-free survival and overall survival. This is like discovering a hidden oasis in a desert, providing a source of strength and resilience for patients facing this challenging disease.

The Search for Resilience: Finding Hope in the Desert of Relapsed Ovarian Cancer

This study offers valuable insights into the management of relapsed ovarian cancer. It highlights the importance of carefully selecting appropriate treatment options and maximizing the potential benefits of each therapy. This is like a strategic journey through a complex desert, where each decision and action plays a critical role in achieving the desired outcome.

Managing Ovarian Cancer: A Journey of Awareness and Proactive Care

Individuals at risk of ovarian cancer should be aware of the potential signs and symptoms and seek prompt medical attention. Regular checkups and preventive measures, like maintaining a healthy lifestyle, can play a crucial role in early detection and treatment. Just as a wise desert traveler prepares for their journey, individuals should take proactive steps to safeguard their health and seek guidance from healthcare professionals.

Dr. Camel's Conclusion

This study offers a glimmer of hope in the challenging journey of managing relapsed ovarian cancer. It underscores the importance of carefully selecting appropriate treatment options and emphasizes the need for ongoing research to improve treatment strategies and patient outcomes. Like a resilient camel navigating a harsh desert, patients and their healthcare providers must work together to overcome this challenging disease and find a path toward a healthier future.

Date :
  1. Date Completed 2013-03-29
  2. Date Revised 2022-03-17
Further Info :

Pubmed ID

22910840

DOI: Digital Object Identifier

10.1093/annonc/mds203

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.